AC Immune claims a tau win in Alzheimer’s
But mixed data and a previous failure provide reasons to be cautious.
AC Immune backs alpha-synuclein despite recent setbacks
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
Key third-quarter readouts for big pharma
Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.
Biogen deals the tau pipeline another blow
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
The next wave of amyloid-targeting projects approaches
Acumen is the latest player to take aim at amyloid, but competition is fierce.
Why not bapineuzumab?
Like Aduhelm this long-discontinued amyloid beta MAb reduced brain beta amyloid; so have several other industry projects.
Biogen makes history with Alzheimer’s approval
A green light from the US regulator for aducanumab is a huge boost for Biogen, but not everyone will be celebrating.
Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
Anti-amyloid approaches come back from the dead
Lilly and Roche bask in the reflected glow of aducanumab's benign briefing documents.
